Cameron Frayling

Co-founder @Biofidelity

Cambridge, GB

Biofidelity has developed a simple platform chemistry for liquid biopsy whichcan detect as little as a single molecule of tumour DNA against thebackground of billions of healthy molecules present in a sample of blood.With at least 50x the specificity of gold-standard PCR tests, this uniquecapability enables better targeting of cancer therapies, patient monitoringand early detection of disease and can be deployed on existing instrumentsin labs across the world.With specificity exceeding best-in-class sequencing tests for a fraction of thecost and in a fraction of the time, Biofidelity’s mission is to improvediagnosis, treatment and patient outcomes across a wide range of diseases.Through its low cost and extreme sensitivity, Biofidelity’s unique chemistryopens the possibility for regular monitoring of patients for disease recurrenceand screening of high risk populations, detecting the presence of disease ata far earlier stage than competing technologies and ultimately extending thelives of cancer patients.

McGill University

Bachelor's degree